Statistical modelling for clinical and genetic risk factors for GvHD and survival in a cohort of European HLA matched sibling transplants  by Dickinson, A.M. et al.
ered to the bone marrow as compared with the liver. There was a
linear relationship between the infused dose of Y-90 and the
estimated radiation dose delivered to the BM. Mean absorbed
radiation doses were: bone marrow 10.23  1.8 cGy/MBq; liver
2.67  2.0 cGy/MBq; spleen 7.10  3.75 cGy/MBq. Total ab-
sorbed radiation doses at each Y-90 dose level are shown in Table
1. No additional toxicity due to the additional radiation was seen.
Engraftment: neutrophils 	0.5 by day 13.8 (range 11-22); plate-
lets 	50 by day 12.7 (range 10-22), no graft failures. In one
patient with myeloma, focal uptake of radiolabelled antibody was
seen at sites of disease activity suggesting in vivo targeting of
myeloma. This is consistent with our ﬁnding of CD66 antigen
expression by malignant plasma cells as shown by ﬂow cytometry.
There was a trend to greater disease response as the radiation dose
increased, with a greater proportion of patients at the higher
radiation dose levels achieving a CR. Conclusions: The radiola-
belled anti-CD66 monoclonal antibody showed consistently excel-
lent BM targeting and very low uptake by non-haematopoietic
organs. Up to 30 Gy of radiation was delivered to the BM with no
additional toxicity to other organs. Phase II studies are under way
using the Y-90-labelled anti-CD66 in RIC-allogeneic SCT proto-
cols and for autologous SCT for myeloma.
Table 1. Organ Dosimetry
Dose level
(MBqkg)
Organ Dose in (Gy)
Bone Marrow Liver Spleen
5 4.1 1.4 1.1
10 9.1 1.3 2.4
25 15.6 3.7 12.6
37.5 25.0 7.4 5.1
GVH/GVL
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PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE DESPITE COM-
PENSATORY FUNCTION OF LYMPHOID ORGANS IN VIVO
Beilhack, A.1, Schulz, S.1,2, Baker, J.1, Beilhack, G.F.1,
Nishimura, R.1, Landan, G.1, Baker, E.M.1, Herman, E.I.1,
Butcher, E.C.3, Contag, C.H.4, Negrin, R.S.1 1Division of Blood &
Marrow Transplantation, Stanford University, Stanford, CA; 2Institute
of Pathology, Technical University Munich, Germany; 3Department of
Pathology, Stanford University, Stanford, CA; 4Department of Pediat-
rics, Stanford University, Stanford, CA.
Acute graft-versus-host disease (aGVHD) results from allo-
reactive donor derived T cells attacking targets in the gastroin-
testinal tract, liver and skin. We observed the initiation and
rapid kinetics of aGVHD in a murine model [FVB/N (H-2q)
into irradiated BALB/c (H-2d)] using in vivo bioluminescence
imaging. The transition from the initiation to the effector phase
of aGVHD (day 3-4) was characterized by rapid T cell prolif-
eration and upregulation of gut homing receptors 
47, 
E7
and CCR9 on alloreactive T cells in Peyer’s patches (PP),
mesenteric lymph nodes (LN) and spleen, but not peripheral
LNs. Therefore we asked whether the lack of speciﬁc lymphoid
priming sites would lead to decreased alloreactive T cell inﬁl-
tration in the gut compared to the liver and skin. Using PP
deﬁcient mice, we observed that mesenteric LN and spleen
compensate for the lack of PP as alloreactive priming sites.
Transplantation of PP and LN deﬁcient mice (LT
/) showed
that the spleen alone was sufﬁcient to cause the complete proﬁle
of aGVHD with a time course similar to that of wild-type mice.
Splenectomized mice with intact secondary lymphoid organs
also developed aGVHD. Strikingly, treatment of splenecto-
mized recipients with blocking antibodies against the lymphoid
homing receptors l-selectin and MAdCAM-1 prevented GVHD
with 100% survival (	120 d, P  .0001). Our study shows that
multiple priming sites are involved in GVHD initiation, the
spleen compensating for the lack of PP and mesenteric LN, and
vice versa. In contrast, splenectomy and antibody blocking re-
sulted in a clear survival beneﬁt for all recipients. A.B. and S.S.
contributed equally to this study.
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THE HAPLOIMMUNOSTORM SYNDROME: A DISTINCT CLINICAL ENTITY
SEEN IN HLA-HAPLOIDENTICAL CELLULAR IMMUNOTHERAPY
Colvin, G.A.1, Chung, S.1, Ballen, K.K.2, Dey, B.R.2, Winer, E.1,
Quesenberry, P.J.1 1Roger Williams Medical Center, Department of
Research, Adel Decof Cancer Center, Providence, RI; 2Massachusetts
General Hospital, Boston, MA.
An immune-mediated anti-tumor response is the ultimate goal of
allogeneic transplantation for relapsed, refractory malignancies.
We developed a transplant protocol with less toxicity compared
with standard allogeneic transplantation. We utilized multiple do-
nor lymphocyte infusions after nonmyeloablative HLA-haploiden-
tical stem cell transplantation for refractory disease. We have
performed a total of 41 HLA-mismatched transplants with escala-
tion of the CD3 dose to 2  108 cells/kg using G-CSF primed
product, with a conditioning regimen of 100 cGy total body irra-
diation. Our phase I/II study had 26 with hematologic malignan-
cies. This therapy results in loss of detectable macrochimerism.
Despite this, 13 responses, six major, occurred outside of macro-
chimerism. We have observed a new infusion related clinical entity
named haploimmunostorm (HIS), observed after infusion. This
syndrome occurred in 26 out of 30 (87%) patients with a CD3
dose more than 1  108 cells/kg. In the syndrome, a constellation
of symptoms occurred, some with variable penetrance, in which
hyperpyrexia and malaise were a constant feature occurring as early
as 4 hrs after cell infusion (median of 14 hrs). A morbilliform rash
was seen in 40% of patients. Biopsies revealed no evidence of
hyperacute or acute GVHD. Diarrhea was present in a 20% of
patients; biopsies taken also failed to show any evidence of GVHD.
Transient elevations of liver enzymes occurred in 40% of the
patients usually. Steroids were used successfully if the HIS syn-
drome lasted more than 72 hrs. We used a Bioplex machine and
analyzed 17 separate cytokine levels serially in these patients be-
ginning with pre-treatment levels. Cytokine level analysis showed
up to a 90 fold increase in baseline cytokine levels with signiﬁcant
increases of at least 10 fold in IFN-, IL-10, IL-13, IL-2, IL-5,
IL-6, IL-7, IL-8, MCP-1, and MIP-1. This syndrome appears to
be immunologically based and represents neither hyperacute nor
acute GVHD. This syndrome is different than an engraftment
syndrome reported in some patients undergoing autologous trans-
plant. Engraftment syndrome occurs at time of engraftment, op-
posed to HIS in which may be a rejection syndrome. Engraftment
syndrome is similar to HIS but deviates with presence of capillary
leak and pulmonary inﬁltrates. In summary, we have observed a
new clinical entity that was not previously seen and is a result of the
donors having a relatively intact immune system at the time of cell
infusion.
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STATISTICAL MODELLING FOR CLINICAL AND GENETIC RISK FACTORS
FOR GvHD AND SURVIVAL IN A COHORT OF EUROPEAN HLA MATCHED
SIBLING TRANSPLANTS
Dickinson, A.M.1, Holler, E.2, Rocha, V.3, Hromadnikova, I.4,
Sedlacek, P.4, Kolb, H.-J.5, Pearce, K.F.1 1University of Newcastle upon
Tyne, Newcastle upon Tyne, United Kingdom; 2University of Regens-
burg, Regensburg, Germany; 3Hopital Saint-Louis, Paris, France;
4Charles University, Prague, Czech Republic; 5Ludwig Maximillian
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A cohort of 244 HLA matched sibling transplants from 5
centres within Europe were typed for SNPs or microsatellites
(IL-1R
, IL-4, IL-6, IL-10, IFN, TNF
, TNFR11, and ste-
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roid hormone receptors (VDR and ER
) together with analysis
of NOD2/CARD15 mutations previously shown to be associ-
ated with GvHD and survival; clinical factors such as recipient
age, gender mismatch (female donor/male recipient), CMV sta-
tus, disease stage and stem cell source were included in the
analysis. Statistical modelling was carried out using binary lo-
gistic regression (for GvHD) and Cox regression (for survival).
Step-wise variable selection was used to identify a good set of
predictors of response. The prognostic index was a weighted
linear combination of these predictors and predictive accuracy
assessed for GvHD models. For the total cohort a good predic-
tive model for GvHD II-IV included absence of patient/donor
VDR and presence of patient IFN3/3 genotype; female to male
transplants; PBSC transplant and absence of T-cell depletion
(sensitivity 62%). GvHD associated with reduced intensity con-
ditioning occurred with the presence of patient/donor IL-1R

genotype, absence of VDR-1 donor genotype and absence of T
cell depletion (sensitivity 60%; overall correct prediction 77%).
In the acute leukaemia sub-group presence of patient IL-6 and
IFN genotype and absence of donor VDR-1 genotype inﬂu-
enced GvHD II-IV (64% sensitivity; overall correct prediction
68%). In the sub-group 	16 years the MDR-1 (12 allele A)
together with NOD2/CARD15 mutations inﬂuenced GvHD
outcome (speciﬁcity 58% sensitivity 80% overall correct pre-
diction 71%—Hosmer-Lemeshow test P  .896). Survival mod-
elling (162 of 244), using Cox regression for all data showed that
female to male transplants, donor age 	40 and CMV positivity
together with absence of IFN3/3 donor genotype and presence
of any NOD2 variable in the patient were the most signiﬁcant
variables and the best predictors of decreased survival.
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CHARACTERIZATION OF T CELL SPECIFICITIES RESPONSIBLE FOR DIF-
FERENTIAL GVHD AND ANTI-TUMOR-REACTIVITY INDUCED BY DONOR
LYMPHOCYTE INFUSION
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1Leiden University Medical Center, Leiden, The Netherlands.
Direct cloning using cell sorting of tumor-reactive T cells
from patients successfully responding to donor lymphocyte in-
fusion (DLI) as a treatment of relapsed leukemia or multiple
myeloma after allogeneic stem cell transplantation (SCT) re-
vealed the simultaneous presence of multiple clonal T cell
responses capable of killing the malignant cells during the clin-
ical response. In addition to the presence of known minor
histocompatibility antigen (mHag) speciﬁc T cell responses
against HA-1, HA-2, BCL2-A1 and HY, two new mHag were
identiﬁed. One of the speciﬁcities was characterized to be de-
rived from the endothelial cell growth factor-1 (ECGF-1) gene.
In addition, a new HLA-A2 restricted mHag derived from an
alternative reading frame from a broadly expressed protein was
found to be a target for one of the dominant T cell responses in
a patient with multiple myeloma responding to DLI. Some of
these mHags were exclusively expressed in hematopoietic cells,
whereas others were broadly expressed in both hematopoietic
and non-hematopoietic cells. Despite the broad tissue distribu-
tion of some mHag we found high frequencies of these mHag
speciﬁc T cells up to 3% of circulating T cells also in patients
suffering from only limited GVHD. These results illustrated
that not only the tissue distribution of the proteins indicated the
balance between GVHD and graft versus tumor (GVT) reac-
tivity. Using a panel of primary target cells we demonstrated
differential recognition of non-activated versus activated cells
from patients and donors by T cells speciﬁc for broadly ex-
pressed antigen. The activation state of the target cells corre-
sponded with the recognition by certain T cells against broadly
expressed antigens, whereas T cells recognizing hematopoiesis
speciﬁc mHag like HA-1 were capable of killing both activated
and non-activated hematopoietic cells. Our results illustrate that
T cell responses against broadly expressed antigens can mediate
a GVT reactivity with no or limited GVHD in patients not
suffering from concurrent diseases. These results also explain an
increased susceptibility of target organs for recognition by
mHag speciﬁc T cells during infectious diseases resulting in
increased GVHD.
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DIFFERENTIAL EFFECTS OF ORGAN-DERIVED HOST-TYPE DENDRITIC
CELLS ON ALLOREACTIVE DONOR T CELLS IN A MURINE BONE MAR-
ROW TRANSPLANTATION MODEL
Kim, T.D.1, Zakrzewski, J.L.1, Kochman, A.1, Suh, D.1,
Terwey, T.H.1, Borsotti, C.1, van den Brink, M.R.1 1Department of
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Host dendritic cells are considered critical for the induction of
graft-versus-host disease. In addition to their priming function,
dendritic cells were recently shown to induce organ-tropism de-
pending on their tissue of origin. Here, we sought to examine the
effect of different organ-derived dendritic cells on allogeneic T
cells and their capacity to induce GvHD. FLT3L-expanded host-
type dendritic cells from GvHD target organs (liver, spleen) or
their draining secondary lymphoid tissues (peripheral lymph nodes
for skin, mesenteric lymph nodes for gut) effectively primed naı¨ve
splenic donor-type T cells after short-term coculture in vitro.
Overall levels of alloreactivity as analysed by expression of activa-
tion markers, detection of cytokine secretion and in vitro prolifer-
ation in an MLR were comparable. However, there were signiﬁ-
cantly divergent expression patterns of homing molecules between
gut-derived and all other dendritic cell types. Whereas the expres-
sion of the intestinal homing molecule LPAM-1 (alpha-4, beta-7
integrin) was signiﬁcantly higher on T cells stimulated with gut-
derived dendritic cells, the expression of E- and P-selectin ligands
was signiﬁcantly lower. Interestingly, the expression of E-selectin
ligands was preferentially induced on CD8 T cells, whereas the
upregulation of P-selectin ligands was comparable on CD4 and
CD8 T cells. Both LPAM-1 subunits were upregulated with
alpha-4 integrin being the highest and being associated with up-
regulation of VLA-4 (alpha-4, beta-1 integrin) which has previ-
ously been implicated in liver homing. However, the latter was not
induced by liver-derived dendritic cells. In a murine bone marrow
transplantation model (B10.BR into B6, 1  106 T cells) these
cultured T cells expectedly induced less aggressive GvHD as com-
pared to naive control T cells with the exception of T cells stim-
ulated with dendritic cells from mesenteric lymph nodes. Survival
in this group was signiﬁcantly shorter than in the spleen, liver and
peripheral lymph node groups and not different from the control T
cell group. In conclusion, we have shown for the ﬁrst time that
dendritic cells can efﬁciently induce speciﬁc homing molecules on
alloreactive T cells and that an induced ‘gut-homing phenotype’
correlates with increased GvHD mortality after murine bone mar-
row transplantation.
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THE DETECTION OF ACTIVATED CIRCULATING CMRF-44 POSITIVE
CD11c DENDRITIC CELLS IS CLOSELY ASSOCIATED WITH THE SE-
VERITY OF ACUTE GVHD AFTER ALLOGENEIC HEMOPOIETIC STEM
CELL TRANSPLANT
Lau, J.1, Sartor, M.1, Vuckovic, S.2, Munster, D.2, Bradstock, K.3,
Hart, D.2 1Westmead Millenium Institute, Sydney, New South Wales,
Australia; 2Mater Medical Research Institute, Brisbane, Queensland,
Australia; 3BMT Service, Westmead Hospital, Sydney, New South
Wales, Australia.
Dendritic cells (DC) are considered central to the development
of graft versus host disease (GVHD) following allogeneic hemo-
poietic stem cell transplantation (alloHSCT). Both donor and host
DC are thought to initiate allogeneic immune responses by pre-
senting host antigens to donor T lymphocytes. We prospectively
studied the potential of the monoclonal antibody CMRF-44 to
identify activated circulating blood DC, as a predictive marker of
acute GVHD. Peripheral blood was taken from 40 patients, twice
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